首页/数据集/Discovery of novel potent triple IKZF1/2/3 degraders for the treatment of hematological cancers

Discovery of novel potent triple IKZF1/2/3 degraders for the treatment of hematological cancers

Name: Discovery of novel potent triple IKZF1/2/3 degraders for the treatment of hematological cancers
Creator: National Center for Protein Science(Beijing)
Published: 2025-01-08T17:03:11+08:00

integrated proteome resources2026-02-07 收录

靶向蛋白降解

血液肿瘤治疗

数据链接：

https://www.iprox.cn/page/project.html?id=IPX0010789000 数据链接链接失效反馈

官方服务：

资源简介：

Discovery of novel potent triple IKZF1/2/3 degraders for the treatment of hematological cancers

应用场景：

提供机构：

National Center for Protein Science(Beijing)

创建时间：

2025-01-08

靶向蛋白降解

PROTAC

Proteolysis-targeting chimeras (PROTACs), heterobifunctional compounds that consist of protein-targeting ligands linked to an E3 ligase recruiter, have arisen as a powerful therapeutic modality for ta

NIAID Data Ecosystem100

Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl‑2 Derived from Nonselective Target Binding Ligands

靶向蛋白降解

凋亡机制

Proteolysis targeting chimera (PROTAC) recruits an E3 ligase to a target protein to induce its ubiquitination and subsequent degradation. We reported success in the development of two PROTACs (C3 and

NIAID Data Ecosystem50

Discovery of Histone Deacetylase 8‑Specific Proteolysis-Targeting Chimeras with Anticancer Activity against Hematological Malignancies

靶向蛋白降解

肿瘤药物研发

Histone deacetylase 8 (HDAC8) has emerged as promising therapeutic target for several malignancies. In this study, we developed two series of cereblon (CRBN)-recruiting proteolysis-targeting chimeras

NIAID Data Ecosystem30

Discovery of a Highly Potent and Selective Degrader Targeting Hematopoietic Prostaglandin D Synthase via In Silico Design

靶向蛋白降解

计算机辅助药物设计

Targeted protein degradation by proteolysis-targeting chimera (PROTAC) is one of the exciting modalities for drug discovery and biological discovery. It is important to select an appropriate linker, a

NIAID Data Ecosystem80

Discovery of LL-K8-22: A Selective, Durable, and Small-Molecule Degrader of the CDK8-Cyclin C Complex

靶向蛋白降解

CDK8-cyclinC抗肿瘤靶点

The CDK8–cyclin C complex is an important anti-tumor target, but unlike CDK8, cyclin C remains undruggable. Modulators regulating cyclin C activity directly are still under development. Here, a series

Figshare2023-03-17 更新30

Discovery of novel potent triple IKZF1/2/3 degraders for the treatment of hematological cancers

资源简介：

相关数据集